NLRP3 inflammasome

Assets acting on this target.

Class
NLRP3 inflammasome inhibitor

The NLRP3 inflammasome is a multiprotein complex assembled inside certain immune cells, particularly macrophages, in response to signals of cellular stress or infection. Once triggered, it activates an enzyme called caspase-1, which in turn converts two precursor proteins into their active, secreted forms: interleukin-1 beta (IL-1β) and interleukin-18 (IL-18), potent messengers that recruit and coordinate further immune activity. Caspase-1 activation can also trigger a form of inflammatory cell death called pyroptosis. This pathway is a central sensor within the innate immune system, the body's rapid, non-specific first line of defense, and it responds to a wide range of triggers, including crystals, metabolic byproducts, and tissue damage signals. Because excessive or chronically active NLRP3 signaling drives tissue injury in numerous conditions, it is an attractive point for therapeutic modulation. Diseases where this mechanism is implicated include gout, atherosclerosis, metabolic and liver disease, and certain neurodegenerative and rare inherited autoinflammatory conditions caused by NLRP3 gene mutations. Small-molecule inhibitors of NLRP3 aim to dampen this upstream node before downstream inflammatory cytokines are produced, distinguishing this approach from therapies that instead neutralize IL-1β itself after it has already been released.

By indication

Related mechanisms

NLRP3 inflammasome drugs compared

5 drugs, stage by indication
5 drugs acting on NLRP3 inflammasome: developer, modality, furthest stage and stage in each indication. Furthest stage first.
DrugDeveloperModalityFurthest stageStage by indication
ABP-745Atom Therapeuticssmall moleculePhase 2Phase 2 in Atherosclerotic Cardiovascular Disease
ParunoflastEli Lillysmall moleculePhase 2Phase 2 in Obesity; Phase 2 in Parkinson's Disease
RuvonoflastRezerasmall moleculePhase 2Phase 2 in Obesity
SelnoflastRochesmall moleculePhase 2Phase 2 in Atherosclerotic Cardiovascular Disease
AZD4144AstraZenecasmall moleculePhase 1Phase 1 in Atherosclerotic Cardiovascular Disease; Phase 1 in Chronic Kidney Disease

← all mechanisms